Reviews/Electrolytes and Hydration/Water slows chronic kidney disease progression
Health · EHYD-HEA-02 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
The question is whether drinking more water slows the worsening of chronic kidney disease. The largest and most direct trial coached people with moderate kidney disease to drink more, and after a year their kidney function had declined just as much as those who drank normally [1]. A trial in people with very early kidney disease found no clear effect either, with only a hint of possible benefit in a small subgroup [3], and a three-year trial in polycystic kidney disease found no slowing of kidney growth [5]. The one supportive reading comes from a re-analysis of old trial data and actually shows water working less well than a drug [8]. Because every direct trial came back without a clear benefit, the panel leaned against the claim, while noting that the main trial admitted it may have been too small to detect a real effect.
The corpus is anchored by a directly on-point randomized trial in stage 3 CKD that was null on its primary outcome, with an adjusted between-group eGFR difference of -0.3 mL/min/1.73 m2 (95% CI, -1.8 to 1.2; P = .74) despite achieving a large separation in urine volume [1]. An early-CKD trial reported no statistically significant eGFR effect, with only a non-significant subgroup trend [3], and a 3-year ADPKD trial found no difference in kidney-volume growth (mean difference -0.97% per year; P=0.18) [5]. An underpowered feasibility pilot in the same program found no significant change in eGFR [7]. The only supportive reading is a post-hoc associative analysis of surrogate relationships that shows water intake alone underperforming tolvaptan [8]. The contested point: The division is between reading the uniform null primary results as evidence against the claim versus preserving uncertainty because [1] explicitly states it 'may have been underpowered to detect a clinically important difference' and [3] reports a trend favouring water in early CKD. Secondary signals in [1] (copeptin P=.01, creatinine clearance P=.01) and the early-CKD trend sit against null primary endpoints.
All 12 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Electrolytes and Hydration, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal and most direct trial [1] was null on its primary eGFR endpoint (between-group -0.3 mL/min/1.73m2, P=.74); the single strongest piece of evidence contradicts the claim.
The ADPKD trial [5] used total kidney volume, a surrogate, not kidney function or clinical progression, and was itself null (P=0.18); surrogate-to-outcome inference is unsupported here.
Where it remains uncertain. The main trial acknowledges possible underpowering [1] and an early-CKD subgroup showed a non-significant trend toward benefit [3], leaving uncertainty rather than clean contradiction.
Aleatory
The early-CKD and renal-functional-reserve subgroup signals in [3] are non-significant and at high risk of being chance findings in a 124-patient trial.
Epistemic
[1] states it may have been underpowered to detect a clinically important difference, so a true small benefit cannot be excluded by its null result.
Inferential
[5] measures total kidney volume and [8] measures urine osmolality and kidney-volume relationships; inferring clinical progression from these surrogates is not established.
The load-bearing papers from a corpus of 12, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal stage 3 CKD RCT: null primary outcome, directly fails to support the claim.
“coaching to increase water intake compared with coaching to maintain the same water intake did not significantly slow the decline in kidney function after 1 year. However, the study may have been underpowered to detect a clinically important difference.”
Panel auditInternal validity: high · scope of inference: Adults with stage 3 CKD (eGFR 30-60) and albuminuria, over 1 year.Key limitations: authors note possible underpowering · 1-year follow-up only · achieved intake separation modest (0.6 L/day)
Independent early-CKD RCT also null on eGFR; positive readings are subgroup trends only.
“No statistically significant data on eGFR depending CIWI were obtained”
Panel auditInternal validity: low · scope of inference: Adults with CKD stage 1-2, stratified by renal functional reserve, over 12 months.Key limitations: primary outcome non-significant · small subgroups · subgroup-driven conclusions · confusing statistical reporting
ADPKD RCT null on kidney volume growth over 3 years (surrogate endpoint).
“there was no difference in the annualized rate of change in height-corrected total kidney volume between the ad libitum (7.8% per year; 95% confidence interval [CI], 6.6 to 9.0) and prescribed (6.8% per year; 95% CI, 5.8 to 7.7) water intake groups (mean difference, −0.97% per year; 95% CI, −2.37 to 0.44; P=0.18).”
Panel auditInternal validity: high · scope of inference: Adults with ADPKD (Mayo class 1B-1E, eGFR >=30) over 3 years.Key limitations: only ~half achieved target intake · no reduction in copeptin (mechanism not engaged) · ADPKD-specific · progression proxied by kidney volume
Underpowered stage 3 CKD pilot: no eGFR effect, consistent with the null main trial.
“We found no significant changes in urine, serum osmolality or electrolyte concentrations, or eGFR.”
Panel auditInternal validity: medium · scope of inference: Adults with stage 3 CKD, feasibility and safety of increasing intake over 6 weeks.Key limitations: feasibility pilot · 6 weeks · n=29 · not powered for eGFR/progression
4 of 12 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The best direct RCT evidence is consistently null while residual underpowering and subgroup trends leave genuine uncertainty rather than outright refutation.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered trial with hard endpoints. Every direct trial here was null or underpowered on function; [1] explicitly flags possible underpowering. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large RCT powered for clinical progression (eGFR slope to kidney failure or dialysis) rather than 12-month eGFR change.
Open question: Does increased water intake slow progression to hard kidney endpoints in an adequately powered trial? Why it is still open: [1] was null but states it may have been underpowered; [7] was a feasibility pilot not designed for progression.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19